Mesenchymal Stem Cells in the Treatment of Pediatric Diseases

Overview

Journal World J Pediatr

Specialty Pediatrics

Date 2013 Aug 10

PMID 23929252

Citations 6

Authors

Guo-Ping Zheng

Meng-Hua Ge

Qiang Shu

Mauricio Rojas

Jianguo Xu

Affiliations

Soon will be listed here.

Abstract

Background: In recent years, the incredible interests in mesenchymal stem cells have boosted the expectations of both patients and physicians. Unlike embryonic stem cells, neither their procurement nor their use is deemed controversial. Moreover, their immunomodulatory capacity coupled with low immunogenicity has opened up their allogenic use, consequently broadening the possibilities for their application. In May 2012, Canadian health regulators approved Prochymal, the first mesenchymal stem cells-based drug, for acute graft-versus-host diseases in children who have failed to respond to steroid treatment. The aim of this article is to review the recent advances in mesenchymal stem cells for pediatric diseases.

Data Sources: A literature review was performed on PubMed from 1966 to 2013 using the MeSH terms "mesenchymal stem cells", "clinical trials" and "children". Additional articles were identified by a hand search of the references list in the initial search.

Results: The following categories are described: general properties, mechanisms of action, graft-versus-host diseases, cardiovascular diseases, liver diseases, inflammatory bowel diseases, osteoarticular diseases, autoimmune diseases, type 1 diabetes, and lung diseases.

Conclusions: Mesenchymal stem cells, owing to their availability, immunomodulatory properties, low immunogenicity, and therapeutic potential, have become one of the most attractive options for the treatment of a wide range of diseases. It is expected to see more and more clinical trials and applications of mesenchymal stem cells for pediatric diseases in the near future.

Citing Articles

Stem Cell Therapy: Current Applications and Potential for Urology.

Wiafe B, Metcalfe P, Adesida A Curr Urol Rep. 2015; 16(11):77.

PMID: 26385812 DOI: 10.1007/s11934-015-0551-5.

Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies.

Heslop J, Hammond T, Santeramo I, Piella A, Hopp I, Zhou J Stem Cells Transl Med. 2015; 4(4):389-400.

PMID: 25722427 PMC: 4367503. DOI: 10.5966/sctm.2014-0110.

Tissue engineered scaffolds in regenerative medicine.

Hosseinkhani M, Mehrabani D, Karimfar M, Bakhtiyari S, Manafi A, Shirazi R World J Plast Surg. 2014; 3(1):3-7.

PMID: 25489516 PMC: 4236978.

Characterizing the dielectric properties of human mesenchymal stem cells and the effects of charged elastin-like polypeptide copolymer treatment.

Adams T, Turner P, Janorkar A, Zhao F, Minerick A Biomicrofluidics. 2014; 8(5):054109.

PMID: 25332746 PMC: 4191366. DOI: 10.1063/1.4895756.

Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis.

Marquez-Curtis L, Janowska-Wieczorek A Biomed Res Int. 2014; 2013:561098.

PMID: 24381939 PMC: 3870125. DOI: 10.1155/2013/561098.

References

Stute N, Holtz K, Bubenheim M, Lange C, Blake F, Zander A . Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use. Exp Hematol. 2004; 32(12):1212-25. DOI: 10.1016/j.exphem.2004.09.003. View

Gonzalez M, Gonzalez-Rey E, Rico L, Buscher D, Delgado M . Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009; 136(3):978-89. DOI: 10.1053/j.gastro.2008.11.041. View

Kern S, Eichler H, Stoeve J, Kluter H, Bieback K . Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006; 24(5):1294-301. DOI: 10.1634/stemcells.2005-0342. View

Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J . Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013; 61(23):2329-38. DOI: 10.1016/j.jacc.2013.02.071. View

Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts A . Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008; 2(2):141-50. DOI: 10.1016/j.stem.2007.11.014. View

English K . Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol. 2012; 91(1):19-26. DOI: 10.1038/icb.2012.56. View

Spaggiari G, Abdelrazik H, Becchetti F, Moretta L . MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood. 2009; 113(26):6576-83. DOI: 10.1182/blood-2009-02-203943. View

Mougiakakos D, Jitschin R, Johansson C, Okita R, Kiessling R, Le Blanc K . The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood. 2011; 117(18):4826-35. DOI: 10.1182/blood-2010-12-324038. View

Hare J, Traverse J, Henry T, Dib N, Strumpf R, Schulman S . A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54(24):2277-86. PMC: 3580848. DOI: 10.1016/j.jacc.2009.06.055. View

10.

English K, Ryan J, Tobin L, Murphy M, Barry F, Mahon B . Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009; 156(1):149-60. PMC: 2673753. DOI: 10.1111/j.1365-2249.2009.03874.x. View

11.

van Poll D, Parekkadan B, Cho C, Berthiaume F, Nahmias Y, Tilles A . Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology. 2008; 47(5):1634-43. DOI: 10.1002/hep.22236. View

12.

Kumar S, Ponnazhagan S . Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defect. Bone. 2012; 50(4):1012-8. PMC: 3339043. DOI: 10.1016/j.bone.2012.01.027. View

13.

Toma C, Pittenger M, Cahill K, Byrne B, Kessler P . Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105(1):93-8. DOI: 10.1161/hc0102.101442. View

14.

Tsai L, Wang Z, Munasinghe J, Leng Y, Leeds P, Chuang D . Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke. 2011; 42(10):2932-9. PMC: 3183311. DOI: 10.1161/STROKEAHA.110.612788. View

15.

Rojas M, Xu J, Woods C, Mora A, Spears W, Roman J . Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol. 2005; 33(2):145-52. PMC: 2715309. DOI: 10.1165/rcmb.2004-0330OC. View

16.

Behnia H, Khojasteh A, Soleimani M, Tehranchi A, Atashi A . Repair of alveolar cleft defect with mesenchymal stem cells and platelet derived growth factors: a preliminary report. J Craniomaxillofac Surg. 2011; 40(1):2-7. DOI: 10.1016/j.jcms.2011.02.003. View

17.

Quevedo H, Hatzistergos K, Oskouei B, Feigenbaum G, Rodriguez J, Valdes D . Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A. 2009; 106(33):14022-7. PMC: 2729013. DOI: 10.1073/pnas.0903201106. View

18.

Tavassoli M, CROSBY W . Transplantation of marrow to extramedullary sites. Science. 1968; 161(3836):54-6. DOI: 10.1126/science.161.3836.54. View

19.

Rupp S, Bauer J, Tonn T, Schachinger V, Dimmeler S, Zeiher A . Intracoronary administration of autologous bone marrow-derived progenitor cells in a critically ill two-yr-old child with dilated cardiomyopathy. Pediatr Transplant. 2008; 13(5):620-3. DOI: 10.1111/j.1399-3046.2008.01024.x. View

20.

Hatzistergos K, Quevedo H, Oskouei B, Hu Q, Feigenbaum G, Margitich I . Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010; 107(7):913-22. PMC: 3408082. DOI: 10.1161/CIRCRESAHA.110.222703. View